Article thumbnail

Effectiveness and Safety of Photoselective Vaporization of the Prostate with the 120 W HPS Greenlight Laser in Benign Prostatic Hyperplasia Patients Taking Oral Anticoagulants

By Jun Ho Sohn, Yong Sun Choi, Su Jin Kim, Hyuk Jin Cho, Sung Hoo Hong, Ji Youl Lee, Tae-Kon Hwang and Sae Woong Kim
Topics: Original Article
Publisher: The Korean Urological Association
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1999). A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate, with a 1-year follow-up.
  2. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention.
  3. Electroresection of the prostate in patients treated with heparin.
  4. (1999). Factors influencing morbidity in patients under-going transurethral resection of the prostate.
  5. Greenlight laser in benign prostatic hyperplasia: turning green into gold.
  6. (2000). High power potassiumtitanyl-phosphate laser vaporization prostatectomy.
  7. High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates.
  8. High-power potassium-titanylphosphate or lithium triboride laser photoselective vaporization prostatectomy for benign prostatic hyperplasia: a systematic approach.
  9. Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomized trial with 4-year minimum long-term followup.
  10. Initial experience with a new 120 W Greenlight TM high-power system for photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia in Korea.
  11. KTP laser versus transurethral resection: early results of a randomized trial.
  12. (1997). Management of anticoagulation before and after elective surgery.
  13. Minimally invasive and endoscopic management of benign prostatic hyperplasia.
  14. morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy.
  15. Nd:YAG laser ablation plus transurethral resection for large prostates in high-risk patients.
  16. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes.
  17. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome.
  18. Photoselective vaporization of the enlarged prostate with KTP laser: long-term results in 240 patients.
  19. (2006). Photoselective vaporization of the prostate: subgroup analysis of men with refractory urinary retention. Eur Urol
  20. Photoselective vaporization of the prostate: the basel experience after 108 procedures.
  21. Postoperative venous thrombosis in benign prostatic disease. A study of 316 patients, using the 125I-fibrinogen uptake test.
  22. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies.
  23. (2004). The development of laser prostatectomy.
  24. The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction.
  25. The efficacy and safety of photoselective vaporization of the prostate with a potassium-titanyl-phosphate laser for symptomatic benign prostatic
  26. Three-year follow-up of laser prostatectomy versus transurethral resection of the prostate in men with benign prostatic hyperplasia.
  27. (1999). Thrombotic risk factors associated with transurethral prostatectomy.
  28. Transurethral prostatectomy: mortality and morbidity.
  29. (1998). Transurethral resection of the prostate in the anticoagulated patient.
  30. Vaporization of prostates of > or =80 mL using a potassium-titanyl-phosphate laser: midterm-results and comparison with prostates of <80 mL.